Abstract Therapeutic plasma exchange (PE) is the accepted therapy for thrombotic thrombocytopenic purpura (TTP). Because not all patients achieve remission, other treatment modalities have been used in addition to PE, but no randomized clinical trial evaluated their efficacy. The aim of this multicentric study was to compare the effectiveness of standard-versus high-dose methylprednisolone as an adjunctive treatment to PE in the acute phase of TTP. Sixty patients with idiopathic TTP were randomized to receive methylprednisolone 1 mg/kg/die intravenous or 10 mg/kg/ die for 3 days, thereafter, 2.5 mg/kg/die in addition to PE. Both dosages of steroids were well tolerated. At the end of induction therapy (day 23), the percentage of patients failing to achieve complete remission was significantly higher in the standard dose (16 of 30) than in the high-dose group (seven of 30). Also, the number of cases without a 591-596 DOI 10.1007/s00277-009-0877-5 good response at day 9 and the number of deaths were higher in the standard-dose arm, but the differences did not reach the statistical significance. Results of present study indicate that the association of PE with high-dose instead of standard-dose steroids reduces the percentage of TTP patients that fail to achieve complete remission.
Introduction
Treatment with plasma delivered by either exchange [1] or infusion [2] dramatically changed prognosis of thrombotic thrombocytopenic purpura (TTP) and transformed this deadly disease into a curable form. Twenty-five years ago, a randomized study by the Canadian Apheresis Study Group compared plasma exchange (PE) with plasma infusion and concluded that the former was significantly better than the latter, with 78% of patients surviving 6 months after entry into the study [3] .
To further improve prognosis of TTP patients, a number of treatments (anti-platelet agents, steroids, cyclosporine, anti-CD20 antibodies, vincristine, cyclophosphamide, intravenous immunoglobulins, etc.) have been empirically added to plasma exchange in single patients or small case series, but none of them has been validated by a controlled study.
Demonstration that an acquired deficiency of the plasma metalloprotease ADAMTS13 induced by autoantibodies against this protein affects most patients of idiopathic TTP [4, 5] gave a rational basis for immunosuppressive therapy and authoritative authors [5, 6] recommended that steroid therapy should be added to PE in the acute phase of this disorder. However, this logical suggestion has not been supported so far by the results of clinical trials.
To fill this gap, we designed a multicentric, randomized study to assess the efficacy of steroids as an adjunctive treatment to PE in the acute phase of idiopathic TTP. Taking into account the common opinion that avoiding immunosuppressant treatment in control patients could be considered no longer ethical, we compared the effectiveness of standard-versus high-dose methylprednisolone.
Patients, materials and methods

Patients
All patients given a diagnosis of idiopathic TTP at 17 Italian medical centres from 2000 to 2006 were considered for entry into this open-label trial. Eligibility criteria were as follows: platelet count <100×10 9 /L, microangiopathic haemolytic anaemia as indicated by red-cell fragmentation on peripheral blood smears and high serum LDH with no other identifiable cause for this (in particular: PTr<1.5, PTTr<1.5, and fibrinogen>100 mg/dL to exclude disseminated intravascular coagulation), creatinine lower than 2 mg/dL, and no associated disease that in the opinion of the attending physician rendered the patient unable to tolerate the treatment. Patients with a history of TTP were not excluded from the study whenever the previous episode did not occur in the last 3 months.
Main characteristics of enrolled patients are reported in Table 1 . Although the two treatment arms were wellbalanced for what it concerns blood cell counts, LDH levels, age, and the presence of fever at onset, both neurological involvement and female sex were more frequent in the high-dose methylprednisolone group. Although, to the best of our knowledge, no study demonstrated that these parameters affect TTP prognosis, we cannot exclude that these differences interfered with the results of our trial.
The study was approved by the ethical committee of the IRCCS Policlinico San Matteo Foundation, Pavia, and a written informed consent was obtained from all patients.
Study design
Apheresis treatment consisted of daily 1.5 plasma volume exchanges on the first 2 days, then single volume exchanges on five of the next 7 days. Fresh frozen plasma was used as replacement fluid in the first procedure, while cryosupernatant [7] was used in the following exchanges. Cryosupernatant was used based on a pilot study by the Canadian Apheresis Group suggesting that this replacement fluid was more effective than fresh frozen plasma [7] . However, a subsequent, randomized study by the same group failed to confirm this finding and concluded that the two treatments were equivalent [8] .
Patients received aspirin (5 mg/kg/die intravenous; i.v.) whenever their platelet count was higher than 30×10 9 /L. Misoprostol (200 mcg orally four times daily) was used to prevent gastric ulceration, while ranitidine was administered intravenously when oral administration was not possible. Packed red cells were transfused in order to maintain haemoglobin level above 8 gr/dL. Platelet concentrates were not permitted, with the only exception of patients with very low platelet counts and life-threatening haemorrhages.
At admission, patients were centrally randomized (1:1 web-based randomization with the sequence of treatments randomly permuted in blocks of varying size) to standarddose (1 mg/kg/die i.v.) or high-dose methylprednisolone (10 mg/kg/die i.v. for 3 days, thereafter 2.5 mg/kg/die i.v.). Whenever possible, methylprednisolone was administered after PE. In case corticosteroid treatment was required before PE, it has been assumed that half of the drug was removed during the procedure and subsequent administration was calculated accordingly to reach the programmed daily dose.
Response to therapy was first evaluated at day 9, after seven PEs, according to the following criteria: good response, defined as platelet count more than 100×10 9 /L for two consecutive days without deterioration in the neurological status; poor response, defined as platelet count between 50 and 100×10 9 /L with an increase in platelet count of more than 100% with respect to baseline without neurological worsening; no response, defined as platelet count less than 50×10 9 /L or platelet increase less than 100% with respect to baseline and/or neurological worsening.
Patients with good response at day 9 received five additional PEs during the next 2 weeks and continued for 1 week the standard-or the high-dose methylprednisolone therapy according to randomization, then half a dose for an additional week. Patients with poor response underwent seven PEs during the next 2 weeks and continued steroid therapy as patients with good response. Non-responding patients exited the study and were treated at their physicians' discretion.
Patients were finally evaluated at day 23 for complete remission, defined as an increase of platelets to more than 150×10 9 /L, normalisation of LDH value and improvement in neurological status.
Study end points and statistical analysis
Primary end point was failure to achieve "good response" at day 9 after a course of seven PEs. Secondary ends points were "less than complete response" or death at day 23.
Data were presented as counts and percent if categorical and as median and 25th-75th percentiles if continuous. The two-sided exact Fisher's test was used to test the statistical significance of the differences in the outcomes between the two groups. The 95% confidence intervals (95% CI) for the differences between the two treatment groups were also computed. Analyses were done by intention to treat. Stata 10 (StataCorp, College Station, TX, USA) was used for computation. A p value<0.05 was considered statistically significant. Statistical analysis was performed by a blinded data analyst.
Concerning sample size, we calculated that 30 patients per group would be able to elicit a risk difference of 37% (95%CI 13-60%) when the rate of failure to achieve good response at day 9 in the standard dose group is 60%, with a 80% power and a two-sided significance level of 5%.
Results
Thirty patients have been randomized to both standard-dose and high-dose methylprednisolone. All subjects allocated to high-dose treatment received intervention, while one subject allocated to standard-dose died immediately after randomization. Both treatments were well tolerated and no patient had side effects requiring treatment discontinuation. In particular, although our patients did not receive prophylactic antibiotics during PE, no infectious episode has been reported. At day 9, failure to achieve "good response" occurred in 13 of 30 patients (43.4%) receiving standard steroid dose (four deaths, five "no responses" and four "poor responses") and in seven of 30 (23.4%) receiving highdose therapy (one death, two "no responses" and four "poor responses"). At day 23, failure to achieve complete remission were 16 (53.4%) in the standard-dose arm and seven (23.4%) in the high-dose arm. Four patients (13.3%) randomized to standard steroid dose and one patient (3.3%) randomized to high-dose treatment died. The reasons for death were thrombotic (three patients) or haemorrhagic (two patients) intracranial events. Table 2 shows the statistical significance of the differences observed between the two treatment groups.
Discussion
This randomized, multicentric study has shown that the association of PE with intensive methylprednisolone treatment reduced the risk of treatment failure with respect to standard-dose corticosteroids. The advantage of high-dose over standard-dose at day 9 of treatment was relevant but not significant, while the outcome of intensive treatment was significantly better at the end of the study, at day 23, with 76.6% vs. 46.6% of patients achieving complete remission. Also, final survival was better in the high-dose group (96.7% versus 86.7%), but the difference did not reach the statistical significance due to the little number of deaths in both arms.
Very few prospective clinical trials have been performed in TTP, and comparing their results with those of present study is hampered by differences in the study designs. However, the Canadian Apheresis Group recently performed a randomized, prospective trial to assess whether cryosupernatant is better than fresh frozen plasma as replacement fluid for PE [8] . Patients received seven PEs during the first 9 days; antiplatelet therapy was optional while steroid were prohibited. Thus, the major difference between the cryosupernatant arm (28 patients) of the Canadian study and present trial is that our patients received corticosteroids. In both studies, an assessment of treatment outcomes has been performed at day 9 and a close comparison is therefore possible at this time. It shows that the percentage of patients with more than 100×10 9 platelets/L was higher in Italian patients treated with highdose steroids (76.6%) than in Canadian patients (62%). Interestingly, the percentage of Italian patients receiving standard-dose methylprednisolone that reached this platelet level was a little lower (56.6%) than Canadian patients. This comparison confirms the efficacy of high-dose steroid, but also suggests that standard-dose methylprednisolone did not improve the effect of PE alone.
Since the Canadian study did not show an advantage to the use of cryosupernatant instead of fresh frozen plasma, we can also compare the results of present investigation with those of a previous trial of the Italian Cooperative Group for TTP [9] . In this study, patients were treated with 2 mg/kg/die methylprednisolone in addition to PEs with fresh frozen plasma and were randomized to receive or not receive anti-platelet agents. At the end of induction therapy, the percentage of complete remissions in the 35 patients randomized to anti-platelet drugs (60%) was lower than in the high-dose steroids arm of present study (76.6%), but higher than in the standard-dose arm (46.6%). Thus, our intensive steroid treatment obtained better results than the 2 mg/kg/die prednisone regimen of the previous one, which, in turn, resulted in a percentage of remission higher than standard-dose steroid therapy of present study.
A few other studies examine the results obtained in little case series by the association of PE with 1 mg/kg/die prednisone and describe percentages of complete remission much higher [10] or lower [11] than those obtained by us. However, differences in the enrolling criteria and in the definitions of response, as well as in the timing of response evaluation, preclude a direct comparison. Anyway, we cannot exclude that a remission rate lower than expected in our standard-dose arm overestimated the benefit deriving from high-dose prednisone.
In conclusion, comparison of present study with the few previous comparable trials supports the hypothesis that intensive therapy with methylprednisolone improves PE effectiveness, but does not solve the doubts as to whether lower doses increase the percentage of remission with respect to no steroid treatment.
Effectiveness of high-dose corticosteroids in TTP is supported also by other published studies.
In 1991, Bell et al. [12] showed that 200 mg of prednisone per day as a sole treatment achieved remission in 48-72 h in 30 of 54 TTP patients lacking central nervous system abnormalities other than headache. Moreover, Rojnuckarin et al. [13] observed rapid and complete responses by pulse, high dose dexamethasone alone in two patients refractory to PEs. Finally, Toyoshige et al. [14] observed a prompt response to 1 g per day of methylprednisolone in one patient who had previously failed to respond to both plasma infusion and PE.
The quick haematological response of TTP to high-dose corticosteroid treatment suggests that its mechanism of action is not the inhibition of antibody production. Unfortunately, we were unable to monitor the levels of ADAMTS13 activity and inhibiting antibodies in our patients, but in the two already cited patients described by Rojnuckarin et al. [13] , high-dose dexamethasone induced remission without affecting deficiency of ADAMTS13 activity. To explain this phenomenon, it has been suggested that down regulation of various cytokines involved in TTP pathogenesis and/or reduction of endothelial cells activation could be the mode of action of high-dose steroids in this disorder [13, 15] . However, no experimental data supported this hypothesis, so far. Interestingly, a non-immunological mechanism of action in TTP has been suggested also for cyclosporine, in that it induced remission in some patients independently from improvement in ADAMTS13 activity and suppression of the inhibitor [16] .
Disclosure that an acquired defect of ADAMTS13 induced by autoantibodies affects most patients with idiopathic TTP represented a major advance in understanding the pathogenetic mechanisms of this disorder. However, contrasting results have been obtained by the few studies aimed at establishing whether ADAMTS13 testing during the acute episode helps to identify patients' prognosis and can be used to guide their management [17] [18] [19] [20] . On this basis, there is general agreement that all patients in the acute phase have to receive the most effective treatment [21] , and we suggest that, at least presently, the best option is represented by concomitant PE and high-dose corticosteroids. At the opposite, three clinical studies clearly showed that patients with severe ADAMTS13 deficiency during remission have a much higher likelihood of relapse [22] [23] [24] . Since reports of single patients or small case series suggested that chimeric anti-CD20 monoclonal antibodies or cyclosporine help to restore normal ADAMTS13 activity and prevent recurrences, it may be that administration of these drugs to patients with a persistent defect of ADAMTS13 improves their longterm prognosis. Obviously, randomized clinical trials are required to confirm this hypothesis.
In conclusion, we suggest that the association of highdose corticosteroids with PE improves the short-term prognosis of patients with an acute episode of idiopathic TTP with respect to both PE alone and PE associated with standard doses of steroids. Identifying the best therapeutic approach to the patients that fail to respond to this treatment, as well as a treatment for reducing recurrences in the subjects at risk, warrants further investigation.
